Eichenauer DA, et al. - In order to reduce toxic effects while maintaining the protocol's efficacy, researchers modified the escalated BEACOPP regimen (eBEACOPP; bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and implemented brentuximab vedotin. In this study, both eBEACOPP variants met the co-primary efficacy endpoints. A more favourable toxicity profile was particularly evident with the BrECADD regimen. They thus selected this regimen to challenge standard eBEACOPP for the treatment of advanced classical Hodgkin's lymphoma in phase 3 HD21 study by the German Hodgkin Study Group.